Summary A set of monoclonal antibodies was constructed by immunising mice with peptide fragments of the c-myc oncogene product. One such antibody, Myc 1-6E10 was shown to bind to a 62,000 dalton protein identifiable with the c-myc product (p62c-mYc). The antigen recognised was not destroyed by paraflin wax embedding. Myc 1-6E10 was used to characterise the distribution of p62C-fYC in archival testicular tumour material. Normal testes expressed only small amounts of p62c-mYc. Seminomas showed increased nuclear and cytoplasmic staining. Undifferentiated teratoma showed little activity, whereas p62c-mYc was abundant in the nuclei of differentiating epithelial structures, yolk sacs and embryoid bodiesl Only small amounts of p62c-"Yc were seen in the tumours of 5 patients who subsequently died from their disease.
The demonstration that human cancer cells may show abnormal expression of unique segments of DNA, called oncogenes, provides an exciting new avenue for clinical investigation. Over 25 of these genes have now been identified, molecularly cloned and sequenced (Krontiris, 1983; Hamlyn & Sikora, 1983) . Changes in the coding or control regions of these genes have been implicated in the development of cancer (Cooper & Lane, 1984; Bishop, 1984) . Several molecular mechanisms resulting in either the increased production of normal oncogene products or the development of aberrant proteins that subvert the normal growth control processes have now been uncovered (Der & Cooper, 1983; Stewart et al., 1984b) . These include gene amplification, translocation, mutation and rearrangement. Such changes have been documented in fresh tumour biopsies from patients as well as cultured cell lines (Rothberg et al., 1984; Favera et al., 1982) . Using DNA hybridisation techniques, the Nmyc gene has found to be amplified up to 100-fold in neuroblastoma (Schwab et al., 1983) and retinoblastoma (Lee et al., 1984) . In one patient with chronic myelocytic leukaemia, the c-myc sequence was amplified 16-fold and rearranged within the genome during episodes of transformation (McCarthy et al., 1984) . Oncogene RNA transcripts have also been measured in fresh tumour material. K-ras and H-ras mRNA has been found elevated in colonic carcinoma, colonic polyps (Spandidos & Kerr, 1984) and breast cancer (Spandidos & Agnantis, 1984) . Most interest has surrounded the ras and myc genes as considerable variation has been found in the quantity of their transcripts in clinical biopsies at the RNA level (Slamon et al., 1984) .
DNA and RNA hybridisation analysis is difficult to perform with many clinical samples. Low copy number genes and message cannot be detected with current methods. Hybridisation techniques cannot normally be applied to fixed embedded material stored in pathology departments. Furthermore they tell us nothing about the ultimate concentration and distribution in the cell of the gene product. The structure and function of these proteins are now under active investigation. At least one is related to a growth factor (c-sis) (Waterfield et al., 1983) and another (c-erb B) to the internal component of the surface receptor for a growth factor (Downward et al., 1984) . The c-myc gene product is particularly intriguing with regard to human cancer. There is now evidence that this protein is associated with cell division and differentiation. The level of c-myc RNA increases when cells are stimulated into division (Kelly et al., 1983) . Both mRNA transcripts and the protein itself have unusually short half-lives of 20 to 30min (Rabbitts et al., 1985) , a prerequisite for their putative cell cycle control function. Furthermore the protein appears to be associated with cell nuclei, a likely site for such control (Pauza & Evan, submitted for publication).
In order to examine the relevance of c-myc in clinical samples a set of mouse monoclonal antibodies against the c-myc protein was constructed (Evan et al., 1985) . The DNA sequence of the cmyc gene was used to determine the amino acid structure of the c-myc oncoprotein. Peptides of between 10 and 18 amino acids long were synthesized. The regions chosen for synthesis and immunisation were predicted to be exposed within the intact molecule by assessing the relative hydrophilicity of different parts of the sequence. Mice were immunised to produce monoclonal antibodies (MCAs). Six MCAs were shown to bind to a 62,000 dalton protein identifiable with the c-myc product (p62c-mYc). These MCAs are currently being used to isolate and functionally characterise the c-myc protein.
In this report we demonstrate that one of these antibodies, Myc 1-6E10, can be used to detect p62c-mYc protein in archival material from pathology laboratories. Because of the implication of this protein in growth and differentiation we chose to study tumour samples from patients with testicular cancer. Tumours of the testis arise predominantly from cells of the germ cell lineage (Ellis & Sikora, 1985 
Monoclonal antibody
Peptide synthesis, the immunisation protocol and screening procedures for deriving Myc 1-6E10 are described elsewhere (Evan et al., 1985) and summarised in Figure 1 . Hybridoma cells were grown in the ascites fluid of female BALB/c mice. The antibody was purified by octanoic acid precipitation followed by ammonium sulphate concentration. Purified antibody was adjusted to a concentration of 2mgml-1 in PBS with 0.001% sodium azide, aliquoted and stored at -20°C. A control mouse immunoglobulin of the same sub-class (IgG1K) was obtained from ascites fluid of the mouse myeloma line X-63 (Kohler & Milstein, 1975 Figure 1 Schema for peptide immunisation.
Synthetic Peptides
Immunisation the production of MCA by in methanol, washed and incubated for 20 min in diluted normal serum. Excess serum was blotted and the sections incubated for 60min with 100p1 Myc 1-6E10 diluted 1/500 in PBS, 1% BSA and 0.25% Triton X-100 (pH 7.3). Sections were washed and then incubated with a biotinylated rabbit anti-mouse immunoglobulin. After a further wash, sections were incubated for 45min with the Vectorstain ABC reagent. A final incubation in diaminobenzidine (100mg in 200ml 0.5% hydrogen peroxide solution) was performed for 30 min and the sections washed with tap water and counterstained in Mayer's haemalum for 60 sec.
Results

Specificity controls
Most seminomas and teratomas showed considerable staining using Myc 1-6E10 when compared to normal testis. An irrelevant mouse monoclonal immunoglobulin (X63 IgG) of the same immunoglobulin subclass showed no binding. Staining by Myc 1-6E10 was blocked by the addition of 1 yg of the peptide used as the immunogen added to 100lp of antibody prior to its addition to tumour sections (Table I) . (Figure 2a p62c-Yc present in small amounts in some spermatocytes showed little or no staining.
gonia ( x 400).
Malignant teratoma
There was considerable variation in staining intensity between different parts of individual tumours in the 21 teratomas examined. Undifferentiated areas showed little p62c-mYc activity, ofter less than the basal spermatogonia of normal testes. Areas of greatest intensity were clustered at sites of outgrowth of differentiating epithelial structures (Figure 4ab; Figure 5 ). Certain tumours, especially those with yolk sac differentiation, showed intense staining (Figures 6a, b) . Little or no staining was seen in areas of trophoblastic differentiation (Table II) .
No correlation of p62c-mYc staining was observed between the stage of the disease or the preoperative serum level of human chorionic gonadotrophin.
I-ive patients wno subsequently tied trom tneir disease, and one who is currently undergoing chemotherapy for a recurrence, all had small Figure 3 Section of orchidectomy specimen from a amounts of the p62c-mYc in their tumour.
patient with stage I testicular seminoma ( x 400). 
Discussion
The development of monoclonal antibodies to oncogene products provides essential reagents for characterising oncoprotein function and distribution in health and disease. The remarkable conservation of the DNA sequence of individual oncogenes across wide reaches of evolutionary time points to an essential role of their gene products in normal development. Testicular cancer thus provides a biologically as well as clinically relevant system for study.
The examination of c-myc mRNA in the developing human placenta indicates that the peak of myc transcription occurs at 4-5 weeks after conception (Pfeifer-Ohlsson et al., 1984) . Other oncogene RNA transcripts have been found to be elevated in differentiating systems. During liver regeneration the expression of H-ras and c-myc genes are increased (Goyette et al., 1983 ) and the c-fos gene product is specifically elevated in developing bone (Muller et al., 1982) . In most cells the level of c-myc mRNA has been found to be low but increases with the rate of cell division (Pauza & Evan, submitted for publication). In the normal dividing germ cells of the mouse testis very few cmyc mRNA transcripts have been found. The drive to proliferate, at least for several divisions, may therefore come from other gene products. By partially purifying mouse testicular cells it has been demonstrated that c-myc expression was greatest in spermatogonia during the process of their differentiation into spermatocytes (Stewart et al., 1984a ). The histological studies described here suggest a similar pattern in normal human testis.
The control of cell division and differentiation are complex requiring the interaction of many different molecular mechanisms. The c-myc gene product is probably involved in both processes. Normal differentiation of germ cells requires the transient expression of high quantities of p62c-mYc. 
